Literature DB >> 22451237

Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.

Xin Yin1, Bo-Heng Zhang, Shuang-Jian Qiu, Zheng-Gang Ren, Jian Zhou, Xiao-Hong Chen, Ying Zhou, Jia Fan.   

Abstract

BACKGROUND: Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC) is an uncommon subtype of primary liver cancer that has rarely been reported in large-scale clinical studies. The aim of this study was to clarify the clinical features, treatment modalities, and prognosis of cHCC-CC.
METHODS: Included in this study were 113 patients who were histologically diagnosed as having Allen type C cHCC-CC, 103 of whom received liver resection, 6 transarterial chemoembolization treatment, 3 radiofrequency ablation, and 1 palliative supportive treatment. Clinicopathologic features and prognosis of 103 cHCC-CC patients after liver resection were compared with those of 6,679 patients with hepatocellular carcinoma (HCC) and 386 patients with intrahepatic cholangiocarcinoma (ICC) who underwent liver resection during the same period.
RESULTS: The proportion of cHCC-CC in primary liver cancers was 1.5 %. The 103 cases of cHCC-CC were characterized by male predominance, infection with hepatitis virus or presence of liver cirrhosis, and elevated alfa-fetoprotein-findings similar to HCC. However, serum CA19-9 elevation, incomplete capsules, and lymph node involvement were similar to ICC. The 1-, 3-, and 5-year overall survival rates after liver resection were 73.9, 41.4, and 36.4 %, respectively, for patients with cHCC-CC versus 77.5, 53.3, and 41.4 % for HCC patients, and 58.0, 29.1, and 22.3 % for ICC patients (χ(2) = 137.5, P < 0.001). Tumor, node, metastasis system stage (hazard ratio 1.27, 95 % confidence interval 1.08-1.49, P = 0.003) and radical liver resection (hazard ratio 0.31, 95 % confidence interval 0.14-0.68, P = 0.004) were independent prognostic factors for overall survival.
CONCLUSIONS: cHCC-CC has biological behavior and prognosis that are intermediate between HCC and ICC. Radical liver resection can provide a better outcome for this uncommon malignancy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22451237     DOI: 10.1245/s10434-012-2328-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  57 in total

1.  Gallbladder metastatic combined hepatocellular carcinoma and cholangiocarcinoma without primary intrahepatic tumor.

Authors:  Yang Huang; Guang Jian Liu; Ming De Lu; Bing Liao
Journal:  Dig Dis Sci       Date:  2013-05-24       Impact factor: 3.199

2.  Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging.

Authors:  Sun Kyung Jeon; Ijin Joo; Dong Ho Lee; Sang Min Lee; Hyo-Jin Kang; Kyoung-Bun Lee; Jeong Min Lee
Journal:  Eur Radiol       Date:  2018-06-28       Impact factor: 5.315

3.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

4.  Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.

Authors:  Yan-Ming Zhou; Xiao-Feng Zhang; Lu-Peng Wu; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

5.  Histological heterogeneity in primary and metastatic classic combined hepatocellular-cholangiocarcinoma: a case series.

Authors:  Claudio De Vito; Debashis Sarker; Paul Ross; Nigel Heaton; Alberto Quaglia
Journal:  Virchows Arch       Date:  2017-07-13       Impact factor: 4.064

6.  How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?

Authors:  Hong Seon Lee; Myeong-Jin Kim; Chansik An
Journal:  Eur Radiol       Date:  2018-12-14       Impact factor: 5.315

7.  Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with combined hepatocellular-cholangiocarcinoma.

Authors:  Chae Hong Lim; Seung Hwan Moon; Young Seok Cho; Joon Young Choi; Kyung-Han Lee; Seung Hyup Hyun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-02       Impact factor: 9.236

Review 8.  Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma.

Authors:  Yuichi Sanada; Yujo Kawashita; Satomi Okada; Takashi Azuma; Shigetoshi Matsuo
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

9.  Impact of operative and peri-operative factors on the long-term prognosis of primary liver cancer patients undergoing hepatectomy.

Authors:  Li-Ning Xu; Ying-Ying Xu; De-Wei Gao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28

10.  Study of the correlation between H-ras mutation and primary hepatocellular carcinoma.

Authors:  Guode Sui; Xuexiao Ma; Shiguo Liu; Haitao Niu; Qian Dong
Journal:  Oncol Lett       Date:  2012-07-27       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.